Cisplatin, gemcitabine, and treosulfan in relapsed stage IV cutaneous malignant melanoma patients.

Abstract

To evaluate the efficacy of cisplatin, gemcitabine, and treosulfan (CGT) in 91 patients with pretreated relapsed AJCC stage IV cutaneous malignant melanoma. Patients in relapse after first-, second-, or third-line therapy received 40 mg m(-2) intravenous (i.v.) cisplatin, 1000 mg m(-2) i.v. gemcitabine, and 2500 mg m(-2) i.v. treosulfan on days 1 and 8. Cisplatin, gemcitabine, and treosulfan therapy was repeated every 5 weeks until progression of disease occurred. A maximum of 11 CGT cycles (mean, two cycles) was administered per patient. Four patients (4%) showed a partial response; 15 (17%) patients had stable disease; and 72 (79%) patients progressed upon first re-evaluation. Overall survival of all 91 patients was 6 months (2-year survival rate, 7%). Patients with partial remission or stable disease exhibited a median overall survival of 11 months (2-year survival rate, 36%), while patients with disease progression upon first re-evaluation had a median overall survival of 5 months (2-year survival rate, 0%). Treatment with CGT was efficient in one-fifth of the pretreated relapsed stage IV melanoma patients achieving disease stabilisation or partial remission with prolonged but limited survival.

• Authors: J Atzpodien, K Terfloth, M Fluck, M Reitz
• Journal: British journal of cancer (Br J Cancer) Vol. 97 Issue 10 Pg. 1329-32 (Nov 19 2007) ISSN: 0007-0920 [Print] England
• PMID: 17971774 (Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Deoxycytidine
• treosulfan
• Busulfan
• Cisplatin
• Gemcitabine

Topics

• Adolescent
• Adult
• Aged
• Aged, 80 and over
• Antineoplastic Combined Chemotherapy Protocols (adverse effects, therapeutic use)
• Busulfan (administration & dosage, adverse effects, analogs & derivatives)
• Cisplatin (administration & dosage, adverse effects)
• Deoxycytidine (administration & dosage, adverse effects, analogs & derivatives)
• Disease Progression
• Disease-Free Survival
• Dose-Response Relationship, Drug
• Drug Administration Schedule
• Female
• Follow-Up Studies
• Humans
• Injections, Intravenous
• Male
• Maximum Tolerated Dose
• Melanoma (drug therapy, secondary)
• Middle Aged
• Neoplasm Staging
• Neoplasms, Unknown Primary (drug therapy)
• Recurrence
• Remission Induction
• Skin Neoplasms (drug therapy)
• Survival Rate
• Treatment Outcome
• Gemcitabine